PMID- 24074784
OWN - NLM
STAT- MEDLINE
DCOM- 20140529
LR  - 20181202
IS  - 1532-3080 (Electronic)
IS  - 0960-9776 (Linking)
VI  - 22 Suppl 2
DP  - 2013 Aug
TI  - Postmenopausal women with hormone receptor-positive breast cancer: balancing 
      benefit and toxicity from aromatase inhibitors.
PG  - S180-3
LID - S0960-9776(13)00170-7 [pii]
LID - 10.1016/j.breast.2013.07.035 [doi]
AB  - Extensive clinical trial experience is available for aromatase inhibitors (AIs) 
      in postmenopausal women upon which to evaluate the balance of potential benefit 
      and toxicities. A meta-analysis revealed an advantage for AIs over tamoxifen in 
      the monotherapy setting for recurrence but not breast cancer mortality, and an 
      advantage in both of these parameters for switching to an AI after several years 
      of tamoxifen. Importantly, no indication of a deleterious effect of AIs was 
      identified in terms of death without recurrence in these meta-analyses. Regarding 
      serious adverse events (AEs), there are data indicating an increase in 
      cardiovascular AEs and bone fractures but a lower incidence of thromboembolic 
      phenomena and endometrial cancer with AIs vis-a-vis tamoxifen. There does not 
      appear to be a difference in cerebrovascular AEs. Musculoskeletal AEs are the 
      most common clinically important AEs as they are the most common cause of 
      discontinuation of therapy, which can have an adverse effect on outcomes. The 
      balance of benefit and toxicity favors the use of AIs in the adjuvant setting but 
      the absolute benefit from AIs can be decreased in patients with advancing age or 
      increasing comorbidities.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Ingle, James N
AU  - Ingle JN
AD  - Division of Medical Oncology, Mayo Clinic, 200 First Street S.W., Rochester, MN 
      55905, USA. Electronic address: ingle.james@mayo.edu.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - Netherlands
TA  - Breast
JT  - Breast (Edinburgh, Scotland)
JID - 9213011
RN  - 0 (Aromatase Inhibitors)
RN  - 0 (Estrogen Antagonists)
RN  - 0 (Nitriles)
RN  - 0 (Triazoles)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 7LKK855W8I (Letrozole)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aromatase Inhibitors/*administration & dosage/*adverse effects
MH  - Breast Neoplasms/*drug therapy/metabolism/mortality/pathology
MH  - Cardiovascular Diseases/chemically induced/epidemiology/pathology
MH  - Chemotherapy, Adjuvant
MH  - Drug-Related Side Effects and Adverse 
      Reactions/epidemiology/*etiology/physiopathology
MH  - Estrogen Antagonists/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Fractures, Bone/chemically induced/epidemiology/pathology
MH  - Humans
MH  - Letrozole
MH  - Mastectomy, Segmental/methods/mortality
MH  - Middle Aged
MH  - Neoplasms, Hormone-Dependent/*drug therapy/mortality/pathology
MH  - Nitriles/administration & dosage/adverse effects
MH  - Postmenopause/drug effects/physiology
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Survival Analysis
MH  - Tamoxifen/administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Triazoles/administration & dosage/adverse effects
OTO - NOTNLM
OT  - Adjuvant therapy
OT  - Aromatase inhibitors
OT  - Breast cancer
OT  - Tamoxifen
EDAT- 2013/10/01 06:00
MHDA- 2014/05/30 06:00
CRDT- 2013/10/01 06:00
PHST- 2013/10/01 06:00 [entrez]
PHST- 2013/10/01 06:00 [pubmed]
PHST- 2014/05/30 06:00 [medline]
AID - S0960-9776(13)00170-7 [pii]
AID - 10.1016/j.breast.2013.07.035 [doi]
PST - ppublish
SO  - Breast. 2013 Aug;22 Suppl 2:S180-3. doi: 10.1016/j.breast.2013.07.035.